News of Note—Vical, FluGen and more

In this week's news of note, Vical announced a restructuring. (Pixabay)

Here's some other vaccine news of note for the week:

> After its Astellas-partnered CMV vaccine failed a late-stage trial last week, Vical announced it's laying off 40 employees and focusing its efforts on an HSV-2 vaccine candidate and an antifungal drug. FierceBiotech story | More

> FluGen is planning a new study in Europe for its universal flu vaccine candidate. Wisconsin State Journal article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The University of Tokyo entered a cancer vaccine partnership with the Kanagawa Cancer Center and BrightPath Biotherapeutics. Release